Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.
A new cancer drug candidate developed by Lawrence Livermore National Laboratory (LLNL), BBOT (BridgeBio Oncology Therapeutics) and the Frederick National Laboratory for Cancer Research (FNLCR) has ...
Google DeepMind announced the launch of AlphaProteo, an AI system to help biological and health researchers design novel, high-strength proteins that bind to target molecules with accuracy and ...
Artificial intelligence (AI)-based drug developer Isomorphic Labs said it has raised $600 million in its first external funding round, with the proceeds expected to accelerate its research and ...
In recent years, artificial intelligence programs for drug design have steadily shown they can help explore far beyond just small-molecule drugs—by illuminating how proteins fold and interact, all the ...
In what Lawrence Livermore National Lab said is “a substantial milestone for supercomputing-aided drug design,” LLNL and BridgeBio Oncology Therapeutics today announced clinical trials have begun for ...
The antibody drug market value is expected to reach $445 billion in the next five years, with over 160 antibodies currently licensed globally for a wide breadth of conditions, including cancer, ...
Throughout the past few decades, antimicrobial resistance has been on the rise as a result of increased antibiotic use. Like an arms race played out on a tiny scale, pathogenic microbes develop ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback